Cambridge Investment Research Advisors Inc. Invests $312,000 in Dynavax Technologies Corporation (NASDAQ:DVAX)

Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 24,044 shares of the biopharmaceutical company's stock, valued at approximately $312,000.

Other large investors have also bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 1,169 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $35,000. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 3,627 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $131,000. Finally, O Shaughnessy Asset Management LLC bought a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $131,000. 96.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DVAX. Wall Street Zen cut Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research report on Thursday, April 17th. Finally, JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Stock Down 2.9%

NASDAQ DVAX traded down $0.32 during mid-day trading on Friday, reaching $10.58. The stock had a trading volume of 3,840,916 shares, compared to its average volume of 2,153,786. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63. The stock has a market cap of $1.27 billion, a PE ratio of -20.35 and a beta of 1.03. The company has a fifty day moving average price of $10.06 and a 200 day moving average price of $11.79. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The firm had revenue of $68.16 million during the quarter, compared to analysts' expectations of $70.01 million. Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. On average, research analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.